July 10, 2025

1 in 4 U.S. Infants Missing Bifidobacterium: Study

Babies who lacked this key gut bacteria were at an increased risk of eczema, allergies, and asthma by age 2.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Herbal Emollient Shows Lasting Relief for Eczema

Clinical trial finds herbal emollients with ginger and cannabidiol reduce itch, improve symptoms, and restore skin barrier in mild atopic dermatitis.

Conexiant

June 25, 2025

AD Itch: A Ten-Year Overview

A decade-long analysis tracked global trends, key authors, drug developments, and growing research volume in studies focused on atopic dermatitis-related itch.

Conexiant

June 23, 2025

What’s the Dose for Hair Regrowth?

A national survey found wide variation in intralesional corticosteroid injection techniques among US hair specialists treating different types of alopecia.

Conexiant

July 02, 2024

Black Docs Lacking Amid Growing Attacks on Diversity Programs

Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.

KFF Health News

July 17, 2024

Cendakimab Shows Promise in Phase II Trial for Atopic Dermatitis

Discover the potential of cendakimab, an anti–interleukin-13 monoclonal antibody, to improve symptoms in adult patients with moderate to severe atopic dermatitis, as demonstrated in a recent phase II clinical trial published in JAMA Dermatology.

Conexiant

January 07, 2025

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Conexiant

April 28, 2025

Delgocitinib Cream Outperforms Alitretinoin in Trial

Topical delgocitinib improved eczema severity scores and caused fewer adverse events than oral alitretinoin in adults with severe chronic hand eczema, according to a phase 3 study.

Conexiant